Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activations

Canadian Cancer Trials Group CRC.7 (Alliance N1048) -- A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision -- was centrally activated on October 17, 2012.

The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX and selective use of the standard treatment depending on the response to the FOLFOX prior to surgery. Target accrual is 1060 patients.

If you would like more information about this study, please contact Barbara Graham, Study Coordinator, at 613-533-6430 or


Canadian Cancer Trials Group IND.211 -- A Randomized Phase II Study of Reolysin in Patients with Previously Treated Advanced or Metastatic, Non-Small-Cell Lung Cancer Receiving Standard Salvage Therapy -- was centrally activated on October 15, 2012.

The primary objective of this study is to evaluate the effect of reolysin in combination with either docetaxel or pemetrexed on the progression free survival of patients with advanced or metastatic non-small-cell lung cancer.

This trial is open in a select number of Canadian Cancer Trials Group participating centres. Target accrual is 150 patients.